4-AcO-DMT

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-24srcTentative identification of in vitro metabolites of O-acetylpsilocin (psilacetin, 4-AcO-DMT) by UHPLC-Q-Orbitrap MS
5. 2026-09-24srcChemistry and Structure-Activity Relationships of Psychedelics.
6. 2026-09-24srcDesigner drugs: mechanism of action and adverse effects
7. 2026-09-24srcElucidating the Phase I metabolism of psilocin in vitro
8. 2026-09-24srcIn-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin
9. 2026-09-24srcClinical Pharmacokinetics of Psilocin After Psilocybin Administration: A Systematic Review and Post-Hoc Analysis
10. 2026-09-24srcSafety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances
11. 2026-09-24srcStructure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor
12. 2026-09-24srcA non-hallucinogenic LSD analog with therapeutic potential for mood disorders
13. 2026-09-24srcReceptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens
14. 2026-09-24srcRewarding Effects of the Hallucinogen 4-AcO-DMT Administration and Withdrawal in Rats: A Challenge to the Opponent-Process Theory
15. 2026-09-24srcThe polypharmacology of psychedelics reveals multiple targets for potential therapeutics
16. 2026-09-24srcStructure-Activity Relationships for Psilocybin, Baeocystin, Aeruginascin, and Related Analogues to Produce Pharmacological Effects in Mice
17. 2026-09-24srcReceptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
18. 2026-09-24srcImprovements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin
19. 2026-09-24srcBis(4-acetoxy-N,N-dimethyltryptammonium) fumarate: a new crystalline form of psilacetin, an alternative to psilocybin as a psilocin prodrug
20. 2026-09-24srcPsilocin - The 'real deal' or an extraction byproduct
21. 2026-09-24src5-HT2A receptors in the prelimbic cortex VIP-expressing interneurons: A mechanism for psychedelic-induced innate fear attenuation
22. 2026-09-24srcA Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
23. 2026-09-24srcIn vivo validation of psilacetin as a prodrug yielding modestly lower peripheral psilocin exposure than psilocybin
24. 2026-09-24srcHallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives
25. 2026-09-24srcAnti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
26. 2026-09-24srcPsilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue
27. 2026-09-24srcPharmacokinetics of Psilocybin: A Systematic Review
28. 2026-09-24srcMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.
29. 2026-09-24src4-AcO-DMT (Psilacetin) - Erowid Basics
30. 2026-09-24src4-AcO-DMT
31. 2026-09-04issueIssued emergency
32. 2026-09-04issueIssued info_card
33. 2026-09-04issueIssued notice
34. 2026-06-04proposal40 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
35. 2026-06-04publicationPublication — backfill
36. 2026-04-19revisionRevision 1

The same entries, as forms: six forms.